Regenerative Research Roundup - October 2026
Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in quick-to-read digest.
This month, we explore:
Treatment durability of PRP and HA
The growing importance of platelet dose when assessing outcomes
One-year outcomes following the GPS III PRP system
Orthobiologics serving as adjuncts during cartilage-preservation surgery
Preclinical evidence supporting Prolotherapy + HA combination for OA
Let's dive in!
Platelet-Rich Plasma Provides Small but Superior Short-term Pain Relief and Functional Improvement Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis
Arthroscopy // LOE: II
This meta-analysis compared PRP and hyaluronic acid injections for intra-articular knee injections for osteoarthritis across 21 randomized controlled trials. Primary outcomes were measured as changes in pain and function scores across the VAS, WOMAC and KOOS scales at 3 and 6 months, with follow-up at 12 months post-injection.
Key Findings:
PRP showed more durable pain reduction at 12 months on the VAS scores
WOMAC pain and function favored PRP at all timepoints, compared with HA
Clinical Perspective:
Unsurprisingly, PRP has greater durability for symptom management. Interestingly, the authors performed a sub-analysis and attributed higher platelet concentrations and leukocyte-rich and activated preparations as performing favorably at the 12-month mark. An in-depth look showcases false attribution of dose-driven outcomes to concentration: 9.48 billion platelets total (Su et al. 2018), >15 billion platelets total (Duymus et al. 2017), and 10.6 billion platelets total (Yaradilmis et al., 2020).
ACCESS HERE: https://arthroscopyjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/arj.70520?saml_referrer
Editorial Commentary: Platelet-Rich Plasma Outlasts Hyaluronic Acid for Knee Osteoarthritis, but the Product, Not the Acronym, Is the Prescription
Arthroscopy // LOE: V
This editorial commentary discusses the growing body of evidence comparing PRP with HA and the challenges involved in these comparisons. PRP is often discussed as a single universal treatment, despite substantial variation in platelet dose, volume and concentration, leukocyte content and preparation systems.
Points of Discussion:
Comparing PRP with HA may be the wrong approach; they differ mechanistically; PRP delivers growth factors, HA for viscoelasticity, with both mediating different inflammatory pathways
Platelet concentration and platelet dose are not interchangeable concepts, dose is the primary driver of outcomes, and often concentration is falsely attributed
Clinical Perspective:
It’s quite refreshing to see the clinical consensus catch up to the evidence. When you administer PRP, you’re administering a specific blood-derived biologic product with a defined cellular composition, platelet dose, volume, and treatment schedule. Those characteristics define the intervention.
Preliminary One-Year Observational Outcomes After GPS Leukocyte-Rich Platelet-Rich Plasma Injection for Kellgren Lawrence Grade II and III Knee Osteoarthritis: A Japanese RealWorld Case Series
Orthopedic Reviews // LOE: IV
This Japanese case series evaluated one-year patient-reported outcomes after a single injection of intra-articular GPS leukocyte-rich PRP in 20 patients with KL grades II-III knee OA. The primary outcome was change in NRS pain, and secondary outcomes included KOOS, responder status and adverse events.
Key Findings:
NRS pain improved from 4.6 to 2.7 at one year and KOOS quality-of-life scores improved significantly
46.7% of patients achieved at least a 30% reduction in pain.
13.3% of patients reported worsening pain, 20% reported injection-site pain
Clinical Perspective:
This study evaluates how a real-world leukocyte-rich PRP system performs in a small group of patients. Of note, injecting leukocyte-rich PRP in a joint is likely responsible for patients experiencing flare-ups and pain and swelling during/post injection. This trend is observed in LR-PRP compared with HA but is absent with LP-PRP compared with HA (Nakagawa et al., 2026) –that preparation distinction is a very simple switch for clinics, and relief for patients.
Orthobiologic Injections Adjunctive to Cartilage-Preserving Surgery May Improve Outcomes for Focal Knee Chondral Defects: A Systematic Review of Randomized Controlled Trials With Subgroup Meta-analyses
Arthroscopy // LOE: II
This systematic review evaluated whether orthobiologic injections improve outcomes when used alongside cartilage-preserving surgery for focal knee chondral defects. Five RCTs involving 217 patients were included, assessing PRP, peripheral blood stem cells (PBSCs), adipose-derived mesenchymal stem cells (AD-MSCs), and adipose-derived progenitor cells as adjuncts to microfracture or subchondral drilling.
Key Findings:
PRP combined with microfracture resulted in a statistically significant reduction in pain compared with microfracture alone
PRP demonstrated clinically significant improvement in IKDC score, exceeding the reported MCID
Clinical Perspective:
This review suggests PRP may have an evolving role as an adjunct to cartilage-preserving surgery, having a positive impact on postoperative knee function rather than symptom management. Notably, the biologic characteristics of PRP were poorly reported and highly variable, making it difficult to determine how outcomes were influenced.
Outcomes of Hyaluronic Acid and Dextrose Prolotherapy on Surgically Induced Rat Osteoarthritis: Single Versus Combined Treatment
The Anatomical Record // Preclinical Animal Study
This preclinical study compared the effects of HA, dextrose prolotherapy and combination therapy in a surgically induced rat OA model. Improvements in cartilage structure, joint health and histologic markers were assessed in each treatment arm.
Key Findings:
Both HA and dextrose prolotherapy produced improvements compared with untreated controls
The combination HA + dextrose group demonstrated greater improvements than either treatment alone: cartilage preservation, joint morphology and OA structural markers
Clinical Perspective:
The HA + dextrose combination produced the strongest overall cartilage and joint improvements, suggesting HA may play a biologically active role beyond lubrication and potentially complement regenerative injection therapies. However, these findings are limited to preclinical observations and require confirmation in human studies.
THROWBACK STUDY:
A Study Worth Revisiting PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-analysis of Randomized Controlled Trials
The American Journal of Sports Medicine // LOE: I
This meta-analysis compared PRP with placebo injections for knee osteoarthritis across 18 RCTs including 1,995 patients. Primary outcomes were assessed using WOMAC and VAS scores at 1, 3, 6 and 12 months, with the authors also evaluating whether treatment effects exceeded the minimal clinically important difference (MCID). A sub-analysis separated PRP preparations according to platelet concentration.
Key Findings:
High-dose PRP exceeded the VAS MCID at 3, 6 and 12 months and sustained WOMAC improvement through 12 months
Low-dose preparations did not have the same benefit
Clinical Perspective:
The subgroup analysis reveals a prominent trend in PRP outcome durability with total platelet dosing across regimes. The table below shows a few of the studies and their cumulative platelet doses.
Study | Total Platelet Dose |
~12.48 billion | |
~12.00 billion | |
~16.77 billion | |
~6.72 billion |
ACCESS HERE: https://pubmed.ncbi.nlm.nih.gov/39751394/
Comments